Navigation Links
ProUroCare Medical Completes Multiple Site Clinical Study for Imaging Prostate Abnormalities
Date:10/8/2009

MINNEAPOLIS, Oct. 8 /PRNewswire-FirstCall/ -- ProUroCare Medical, Inc. (OTC Bulletin Board: PUMD and PUMDU) today announced the completion of a National Institute of Health and National Cancer Institute-supported clinical study. The study's purpose was to evaluate the ability of the company's ProUroScan imaging system to visualize and document abnormalities in the prostate detected or monitored by the digital rectal exam (DRE). The results of the clinical study will be submitted to the U.S. Food and Drug Administration (FDA) in support of a 510(k) application in the near future after third party validation of the data.

In an earlier clinical study conducted by Artann Laboratories and Dr. Robert Weiss at the Robert Wood Johnson Medical Center, and published in the peer-reviewed journal Urology, 168 patients were assessed using the ProUroScan system to demonstrate the technology's ability to provide an objective and reproducible image or map of the prostate. In an ensuing meeting with the FDA, a modified clinical study was discussed which would involve imaging at least 40 patients using an enhanced version of the ProUroScan imaging system.

This study, which closed on September 25 with support from Artann Laboratories, ultimately included 57 patients recruited at the following medical centers:

  • University of Minnesota Veterans Affairs Medical Center, Minneapolis, Minn.;
  • Robert Wood Johnson Medical School Division of Urology, New Brunswick, N.J.;
  • AccuMed Research Associates, Garden City, N.Y;
  • Urological Associates of Lancaster, Lancaster, Pa.; and
  • Mayo Clinic, Rochester, Minn.

"While still preliminary, we're very encouraged by the results of our clinical study and believe they compare favorably to the March 2008 study published in Urology," said Rick Carlson, CEO of ProUroCare Medical. "The key value of this technology is the ability of the system to generate a real-time image of the prostate that physicians can use to visualize and document abnormalities in the prostate in patients identified as potentially having prostate abnormalities on digital rectal examination."

More details on the study's purpose, population, criteria and investigators is available at: http://www.clinicaltrials.gov/ct2/show/NCT00822952?term=Prostate+Mechanical+Imaging&rank=1

The ProUroScan imaging system is designed to complement the DRE, and to provide patients with potential prostate abnormalities the ability to have their prostates imaged in real time with records electronically stored for later comparison.

About ProUroCare Medical, Inc.

ProUroCare Medical, Inc. is a publicly traded company engaged in the business of creating innovative medical imaging products. The company's current focus is the ProUroScan prostate imaging system, which is now in clinical trials for the mapping of prostate abnormalities detected by DRE. Based in Minneapolis, Minn., ProUroCare is traded on the OTCBB market.

Safe Harbor Statement

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of ProUroCare's future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause ProUroCare's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability of ProUroCare to find adequate financing to complete the development of its products; the high level of secured and unsecured debt incurred by ProUroCare; the dependence by ProUroCare on third parties for the development and manufacture of its products; and other risks and uncertainties detailed from time to time in ProUroCare's filings with the Securities and Exchange Commission including its most recently filed Form 10-K and Form 10-Q. ProUroCare undertakes no duty to update any of these forward-looking statements.

SOURCE ProUroCare Medical, Inc.


'/>"/>
SOURCE ProUroCare Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ProUroCare Medical Inc. Announces Pricing of Equity Offering
2. ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Globus Medical Raises $110 Million in Series E Financing Round
7. Quark Pharmaceuticals Appoints New Chief Medical Officer
8. Boston University Biomedical Engineers Find Chink in Bacterias Armor
9. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
10. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2, 2016  UCB is pleased to announce that 12 scientific ... 70 th American Epilepsy Society (AES) Annual Meeting, which ... , USA. 1-12 Data being ... of VIMPAT ® (lacosamide) CV and BRIVIACT ® ... the current state of the union of epilepsy care and ...
(Date:12/2/2016)... , December 2, 2016 The iShares ... past losses following Trump,s victory early in November. Less ... fund managers are now predicting an uptick in M&A ... equities to see how they have fared at the ... ), Amicus Therapeutics Inc. (NASDAQ: FOLD ), ...
(Date:11/30/2016)... -- Research and Markets has announced the addition of ... report to their offering. ... Detachable coil embolization is a minimally ... detachable coil embolization treatment of cerebral aneurysms is less invasive and requires ... in the wall of an artery in the brain. This area bulges ...
Breaking Medicine Technology:
(Date:11/30/2016)... ... November 30, 2016 , ... The Fertility Centers ... as a Cigna Infertility Center of Excellence. The Cigna Center of Excellence recognizes ... an honor to be designated a Cigna Infertility Center of Excellence," said Fertility ...
(Date:11/30/2016)... , ... November 30, 2016 , ... "I hate when ... arm while brushing my teeth," said an inventor from Bridgewater, N.J. "I thought that ... develop this handy device." , He developed the patent-pending DEFLECTOR to prevent saliva and ...
(Date:11/30/2016)... FL (PRWEB) , ... November 30, 2016 , ... ... disorder and mental health treatment has announced the opening of a new eating ... partial hospitalization and intensive outpatient treatment for adults and adolescents, both males and ...
(Date:11/30/2016)... ... November 30, 2016 , ... In recent policy debates, increasing ... public policymakers and system stakeholders in many states. To help them understand this ... Index for Workers’ Compensation, Eighth Edition (MPI-WC) . , “If you are a ...
(Date:11/30/2016)... ... 30, 2016 , ... The Clinical Data Interchange Standards Consortium ... Guidance goes into effect next month. Sponsors whose studies start after December 17, ... Catalog. The current FDA Data Standards Catalog specifies the use of CDISC standards: ...
Breaking Medicine News(10 mins):